S. 822: Scientific EXPERT Act of 2025

S. 822 is a federal bill in the 119th Congress. Currently, the Food and Drug Administration (FDA) does not have a formal, required process for regularly facilitating externally led, science-focused meetings specifically to discuss drug development for rare diseases. This bill changes that by requiring… See its sponsors, how members voted, and a plain-English breakdown on PolityLens.